Invention Grant
- Patent Title: TSLP inhibitors
-
Application No.: US16091331Application Date: 2017-04-04
-
Publication No.: US11001624B2Publication Date: 2021-05-11
- Inventor: Savvas Savvides , Rudi Beyaert , Kenneth Verstraete , Harald Braun , Frank Peelman
- Applicant: VIB VZW , UNIVERSITEIT GENT
- Applicant Address: BE Ghent; BE Ghent
- Assignee: VIB VZW,UNIVERSITEIT GENT
- Current Assignee: VIB VZW,UNIVERSITEIT GENT
- Current Assignee Address: BE Ghent; BE Ghent
- Agency: Patent Law Works, LLP
- Priority: EP16163883 20160405
- International Application: PCT/EP2017/057944 WO 20170404
- International Announcement: WO2017/174556 WO 20171012
- Main IPC: C07K14/715
- IPC: C07K14/715 ; A61P17/00 ; A61P37/08 ; A61K38/00
Abstract:
The present invention relates to monomeric fusion proteins comprising the extracellular part of the thymic stromal lymphopoietin receptor (TSLPR) and the extracellular part of the interleukin-7 receptor alpha (IL-7Ralpha) as inhibitors of thymic stromal lymphopoietin (TSLP) activity. The invention relates further to the use of said inhibitors as a medicament in the treatment of—but not limited to—inflammatory diseases, cancer and fibrosis.
Public/Granted literature
- US20190127440A1 NOVEL TSLP INHIBITORS Public/Granted day:2019-05-02
Information query
